🇺🇸 FDA
Patent

US 11591402

Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy

granted A61KA61K2039/505A61P

Quick answer

US patent 11591402 (Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy) held by The Regents of the University of California expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61P, A61P1/04, A61P31/20